Online Program Home
  My Program

All Times EDT

* = applied session       ! = JSM meeting theme

Activity Details

314 * ! Wed, 8/5/2020, 10:00 AM - 11:50 PM Virtual
Statistical Advancements in Neurodegeneration Trial Designs and Analyses — Topic Contributed Papers
Section for Statistical Programmers and Analysts, Biopharmaceutical Section, Biometrics Section, Committee on Applied Statisticians
Organizer(s): Fanni Natanegara, Eli Lilly and Company
Chair(s): Fanni Natanegara, Eli Lilly and Company
10:05 AM Impact of Model Misspecification on Alzheimer Trial Operating Characteristics
Saptarshi Chatterjee, Eli Lilly and Co; Shrabanti Chowdhury, Icahn school of Medicine at Mount Sinai; Fanni Natanegara, Eli Lilly and Company
10:25 AM Multivariate Endpoint, Disease Progress Model and Other New Features of the DIAN-TU Platform Trial
Guoqiao Wang, Washington University in St Louis; Scott Berry, Berry Consultants; Chengjie Xiong, Washington University in St Louis; Jason Hassenstab, Washington University in St Louis; Melanie Quintana, Berry Consultants; Eric McDade, Washington University in St Louis; Paul Delmar, F. Hoffmann-La Roche Ltd; Matteo Vestrucci, University of Texas at Austin; Randall Bateman, Washington University in St Louis; Andrew Aschenbrenner, Washington University in St Louis
10:45 AM TRCPAD: Accelerating Participant Recruitment in Alzheimer’s Disease Clinical Trials Using Machine Learning Techniques
Oliver Langford, University of Southern California; Michael C Donohue, University of Southern California; Gustavo Jimenez-Maggiora, University of Southern California; Reisa Sperling, Harvard Medical School; Jeff Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health; Paul S Aisen, University of Southern California; Rema C Raman, University of Southern California
11:05 AM Construction of Composite End Points to Better Align with Disease Progression and Improve Power
Samuel P Dickson, Pentara; Suzanne B Hendrix, Pentara; Newman Knowlton, Pentara; Noel Ellison, Pentara
11:25 AM Discussant: Richard Entsuah, Merck
11:45 AM Floor Discussion